J. Molner AS
TTAL:MOLNR21.20
EUR
0.00
(0.00%)
ISIN
EE3100109034
Return %
Stock
S&P 500
1Y
-22.63
14.20
3Y
72.36
81.12
5Y
- -
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- Full Time Employees
- 36
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Tallinn Estonia
- IPO Date
- Nov 10, 2022
- Website
- jmolner.com
- Similar Companies
- Business
- J. Molner AS is a specialty pharmaceutical company that engages in the development, manufacturing, and commercialization of complex generic prescription pharmaceuticals and the provision of contract laboratory and analytical chemistry services. The Company operates through two primary business segments: Pharmaceutical Products and Contract Laboratory Services. Its offerings include topical dermatological medications, such as generic prescription creams, ointments, lotions, gels, and topical solutions; sterile injectable preparations and complex dosage formulations; oral liquid medications; analytical chemistry method development and validation; stability storage and testing under International Council for Harmonisation guidelines; raw material and finished product quality control release testing; microbiological testing; and regulatory consulting services for third-party pharmaceutical and biotechnology developers. J. Molner AS focuses its commercial distribution on the United States and Canadian healthcare markets while providing contract research and analytical solutions to partners across Europe and North America. Founded in 2020, the Company is headquartered in Tallinn, Estonia, and operates subsidiary entities including The J. Molner Company LLC in the United States. In recent developments, J. Molner AS has accelerated the commercialization of its proprietary generic portfolio through successive Abbreviated New Drug Application filings and product launches with the U.S. Food and Drug Administration and Health Canada, broadened its contract testing capacity by expanding its laboratory facilities and analytical instrumentation in Tallinn, established strategic commercial distribution partnerships to broaden North American pharmacy and hospital market access, and expanded its operational infrastructure following its listing on the Nasdaq Baltic First North market.